Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020
Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
Corporate Deck September 2020
Corporate Deck August 2020
Investor Presentation Conference Call 6th July, 2020
Investor Presentation Jefferies Virtual Healthcare Conference June 3rd, 2020
Investor Presentation May 2020
JP Morgan Healthcare Conference, San Francisco, 15th January 2020
Press Releases
ObsEva SA Presented Two Late-Breaking Posters at the ASRM 2020 Virtual Scientific Congress October 17-21
press release
October 22, 2020
Geneva, Switzerland and Boston, MA – October 22, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
Read moreObsEva SA Presented Nolasiban Poster at the ASRM 2020 Virtual Scientific Congress October 17-21
press release
October 20, 2020
Geneva, Switzerland and Boston, MA – October 20, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
Read moreObsEva SA to present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference, September 14-16, 2020
press release
September 8, 2020
Geneva, Switzerland and Boston, MA – September 8, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2020
June 9, 2020
ObsEva Annual General Meeting 2019
May 8, 2019
Upcoming Events
Stock Information
Latest Press Release
ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids
If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine…
Read moreInvestor Contact
Media Contact
Media Switzerland & Europe
Shauna Dillon
+41 (0)22 552 1550 Office
+41 79 360 3533 Mobile
Media United States
Shauna Dillon
+41 (0)22 552 1550 Office
+41 (0)79 360 3533 Mobile
Contacts
Media Switzerland & Europe
Shauna Dillon
+41 (0)22 552 1550 Office
+41 79 360 3533 Mobile
Media United States
Shauna Dillon
+41 (0)22 552 1550 Office
+41 (0)79 360 3533 Mobile
Sign up for news
